Table 2.
Emerging therapies for irritable bowel syndrome
| Agent | Mechanism of action | Targeted disorder | Clinical status |
| Peripheral acting agents | |||
| Crofelemer | CFTR inhibitor | IBS-D | Phase 2b complete |
| Linaclotide (MD-1100) | Guanylatecyclase-c agonist | IBS-C | Approved by US FDA in 2012, 30th August |
| Arverapamil (AGI-003) | Calcium channel blocker | IBS-D | Phase 3 |
| Verapamil | Kappa opioid agonist | IBS | Phase 2b complete |
| Mitemcinal | Motilin receptor agonist | IBS-C | Phase 2 |
| Peripheral and central acting agents | |||
| Ramosetron | 5-HT 3 antagonist | IBS-D | Phase 3 |
| TD-5108 | 5-HT 4 agonist | IBS-C | Phase 2 |
| DDP-773 | 5-HT 3 agonist | IBS-C | Phase 2 |
| BMS-562086 | Corticotropin-releasing hormone antagonist | IBS-D | Phase 2 |
| GW876008 | (319) Corticotropin-releasing hormone antagonist | IBS | Phase 2 |
| DDP-225 | 5-HT 3 antagonist and NE reuptake inhibition | IBS-D | Phase 2 |
| GTP-010 | Glucagon-like peptide | IBS pain | Phase 2 |
| AGN-203818 | Alpha receptor agonist | IBS pain | Phase 2 |
| Solabegron | Beta-3 receptor agonist | IBS | Phase 2 |
| Espindolol (AGI-011) | Beta receptor antagonist | IBS (all subtypes) | Phase 2 |
| Dextofisopam | 2,3 benzodiazepine receptors | IBS-D and IBS-M | Phase 3 |
IBS-C: Irritable bowel syndrome with constipation; IBS-D: Irritable bowel syndrome with diarrhea; IBS-M: Mixed irritable bowel syndrome; CFTR: Cystic fibrosis transmembrane conductance regulator; US FDA: United States Food and Drug Administration.